Yamazaki Tatsuo, Tomita Shigeki, Ichikawa Kazuhito, Ono Yuko, Inaba Fujiyuki, Fukasawa Ichio, Imai Yasuo, Imura Johji, Fukui Hirokazu, Fujimori Takahiro, Inaba Noriyuki
Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, Shimotsuga, Tochigi, Japan.
Pathobiology. 2006;73(4):176-82. doi: 10.1159/000096018.
We investigated the relationship between P16-immunostaining patterns and clinicopathological factors in early uterine cervix cancers and assessed whether P16-immunostaining patterns predict the prognosis of the patients with early uterine cervix cancers.
Twenty-nine early squamous cell carcinoma (SCC) specimens of the uterus were examined using immunohistochemistry for P16 expression. The P16-immunostaining pattern was classified into two groups: the homogeneous type and the heterogeneous type. P16-immunostaining patterns were evaluated in different parts of the carcinoma in situ (CIS): the center of the tumor and the front interface of the infiltrating tumor.
All specimens were of the homogeneous type in CIS. The P16-immunostaining pattern was significantly of the heterogeneous type in the front interface of the infiltrating tumor with lymphatic invasion, vascular invasion, lymph node metastasis, and recurrence. Regarding the P16-immunostaining patterns in the front interface of the infiltrating tumor, the patients with the heterogeneous type showed a significantly worse prognosis than the patients with the homogeneous type.
The prognosis of patients with early uterine cervical SCC may be predicted by evaluating the P16-immunostaining pattern in the front interface of the infiltrating tumor.
我们研究了早期子宫颈癌中P16免疫染色模式与临床病理因素之间的关系,并评估P16免疫染色模式是否能预测早期子宫颈癌患者的预后。
采用免疫组织化学方法检测29例早期子宫鳞状细胞癌(SCC)标本中P16的表达。P16免疫染色模式分为两组:均匀型和异质型。在原位癌(CIS)的不同部位评估P16免疫染色模式:肿瘤中心和浸润性肿瘤的前沿界面。
所有标本在CIS中均为均匀型。在伴有淋巴浸润、血管浸润、淋巴结转移和复发的浸润性肿瘤前沿界面,P16免疫染色模式显著为异质型。关于浸润性肿瘤前沿界面的P16免疫染色模式,异质型患者的预后明显比均匀型患者差。
通过评估浸润性肿瘤前沿界面的P16免疫染色模式,可能预测早期子宫颈SCC患者的预后。